Cantor Fitzgerald Weighs in on Tourmaline Bio FY2026 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Tourmaline Bio in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($2.91) per share for the year. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.02) per share.

Tourmaline Bio (NASDAQ:TRML) last announced its quarterly earnings results on Friday, May 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.02.

Several other research firms have also recently issued reports on TRML. Wedbush upped their target price on shares of Tourmaline Bio from $42.00 to $43.00 and gave the company an “outperform” rating in a research note on Friday, March 14th. Chardan Capital restated a “buy” rating and set a $70.00 target price on shares of Tourmaline Bio in a research note on Monday, May 5th. HC Wainwright restated a “buy” rating and set a $50.00 target price on shares of Tourmaline Bio in a research note on Monday, May 5th. Finally, Lifesci Capital began coverage on shares of Tourmaline Bio in a research report on Monday, February 24th. They set an “outperform” rating and a $58.00 price target for the company. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $49.33.

Tourmaline Bio Price Performance

Shares of Tourmaline Bio stock opened at $19.09 on Wednesday. The stock has a market cap of $490.33 million, a price-to-earnings ratio of -6.77 and a beta of 2.05. The firm’s 50-day moving average is $15.93 and its 200 day moving average is $17.28. Tourmaline Bio has a 1 year low of $11.56 and a 1 year high of $29.79.

Institutional Investors Weigh In On Tourmaline Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TRML. Octagon Capital Advisors LP purchased a new stake in Tourmaline Bio in the 1st quarter worth approximately $13,765,000. QVT Financial LP increased its holdings in Tourmaline Bio by 107.1% in the 1st quarter. QVT Financial LP now owns 1,473,369 shares of the company’s stock worth $22,410,000 after acquiring an additional 762,094 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in Tourmaline Bio in the 4th quarter worth approximately $12,168,000. Pictet Asset Management Holding SA increased its holdings in Tourmaline Bio by 69.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 419,883 shares of the company’s stock worth $8,515,000 after acquiring an additional 172,743 shares in the last quarter. Finally, Federated Hermes Inc. increased its holdings in Tourmaline Bio by 13,036.0% in the 1st quarter. Federated Hermes Inc. now owns 121,245 shares of the company’s stock worth $1,844,000 after acquiring an additional 120,322 shares in the last quarter. 91.89% of the stock is owned by hedge funds and other institutional investors.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.